TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01797445
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study: NCT01797445
Drug: E/C/F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Study: NCT01797445
Drug: E/C/F/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT01797445
Drug: E/C/F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT00796250
Drug: Placebo Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
Study: NCT00796250
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
Study: NCT01136863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01016080
Drug: glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg capsules, twice daily, orally
Study: NCT01016080
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg capsules, twice daily, orally
Study: NCT00264420
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
Study: NCT01911728
Drug: MDV3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00107250
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
Study: NCT02533401
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Study: NCT02448251
Drug: AC0010MA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
Study: NCT04259450
Drug: 480 mg AFM24
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study: NCT04475549
Drug: IW-6463 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-6463 tablets administered orally (daily)
Study: NCT04252742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 consecutive injections
Study: NCT01011621
Drug: 0.5% prednisolone acetate cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied over the lesion twice a day for 14 days.
Study: NCT01717066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02474914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide will NOT be given after PD
Study: NCT02195986
Drug: Estradiol Vaginal Cream, 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
Study: NCT02195986
Drug: Estrace® 0.01% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
Study: NCT02195986
Drug: Placebo Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Vaginal Cream ( 1 x 2 g for 7 days)
Study: NCT02782169
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule with excipient to match Pregabalin
Study: NCT00771810
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous injection of 100 ug/kg
Study: NCT00771810
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous injection of 300 ug/kg
Study: NCT00771810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous injection of placebo
Study: NCT01579734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet day for 5 years
Study: NCT02303184
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: suprachoroidal sham procedure
Study: NCT00566683
Drug: diazemuls, pethidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
Study: NCT02521389
Drug: PWT-143
Approvals — FDA: no, EMA: no, PMDA: no
Description: phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
Study: NCT03531320
Drug: D07001-softgel capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Ingredient:Gemcitabine hydrochloride
Study: NCT03246282
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of 0.9% Sodium Chloride Solution
Study: NCT02362048
Drug: ACP-196
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03954782
Drug: Oral treatment of placebo soft capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
Study: NCT01267604
Drug: Recombinant FSH (rFSH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225IU
Study: NCT03515213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01457924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01295450
Drug: Apevinat BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily.
Study: NCT01295450
Drug: Vitamin Complex
Normalized name: Sunmark B Super Vitamin Complex Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
Study: NCT03167307
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
Study: NCT00262587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sugar powder in a placebo inhaler
Study: NCT00097331
Drug: SB683699
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00316082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
Study: NCT02044185
Drug: salvage chemotherapy, total body irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: there are no direct interventions to our patients.
Study: NCT02767674
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 400 mg/m2 IVD d1
Study: NCT03061565
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
Study: NCT01751555
Drug: Regimen:TDF+3TC+EFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF+3TC+EFV for HIV/HBV co-infection
Study: NCT00975312
Drug: Triple combination cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
Study: NCT00975312
Drug: Tretinoin 0.05%
Normalized name: TRETINOIN 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
Study: NCT01922492
Drug: Oral anti-diabetic drugs
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~* Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose.
Study: NCT04305197
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study: NCT01356355
Drug: Herbmed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
Study: NCT01356355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule twice a day daily till ureteral stent in situ
Study: NCT03580889
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between Normal saline, atropine and glycopyrrolate
Study: NCT04305197
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study: NCT02388802
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
Study: NCT00696410
Drug: Zinc Acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels \~10-12.
Study: NCT03275025
Drug: YRA-1909 mid dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mid dose of YRA-1909; daily oral intake for 12 weeks
Study: NCT03275025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo dosing with daily oral intake for 12 weeks
Study: NCT04305197
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study: NCT04322123
Drug: Hydroxychloroquine + azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
Study: NCT03055143
Drug: Ref-08-038
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/ml intravenous infusion
Study: NCT00696384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
Study: NCT02219984
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04639674
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
Study: NCT00356954
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04305197
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Study: NCT04295005
Drug: DPP-4i
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: film coated tablets, specifically Sitagliptin
Study: NCT03139422
Drug: Calcium Dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT03110341
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
Study: NCT02057874
Drug: Magnevist® (Intravenous (IV) administration of MRI contrast agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
Study: NCT02352597
Drug: phytoestrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg of cimifuga racemosa from day 1- 12
Study: NCT02243280
Drug: ABT-493
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02243280
Drug: ABT-530
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02539303
Drug: Yamani-15/5 chemical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
Study: NCT01708616
Drug: RO5285119
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses
Study: NCT01708616
Drug: RO5285119 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses
Study: NCT01847768
Drug: Methacholine Inhalation Challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
Study: NCT02980692
Drug: SUNPG1623 II
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT02980692
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT04497792
Drug: hypoglycemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypoglycemic therapy.
Study: NCT00306033
Drug: Intravenous ImmuneGlobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03040765
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj
Normalized name: ZOLEDRONIC ACID 5MG/BAG 100ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
Study: NCT03748290
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT04237805
Drug: SAF-189s
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg，40mg，80mg，120mg，160mg，210mg，once daily
Study: NCT01320007
Drug: Preset increase in frusemide dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week.
Study: NCT01532128
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BIA 9-1067 (single-dose)
Study: NCT02872701
Drug: OTL38 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Study: NCT04102202
Drug: BOL-DP-o-05
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOL-DP-o-05
Study: NCT04102202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03483987
Drug: Sof+Ledi+R arm
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
Study: NCT03483987
Drug: Sof+Dacla+R arm
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
Study: NCT03483987
Drug: Sof+Velpa+R arm
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
Study: NCT03487406
Drug: Placebo Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
Study: NCT03659448
Drug: SGM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
Study: NCT00612989
Drug: Temodar and O6-Benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose.
Study: NCT02284230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02230956
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (placebo) injection into the intra-articular space of the study knee.
Study: NCT01501669
Drug: Irinotecan, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks
Study: NCT00003260
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003260
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003260
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003260
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00288483
Drug: Policosanol
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04535947
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
Study: NCT01673906
Drug: Diagnostic work up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
Study: NCT02255357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution containing only the excipients of the original solution without Oxytocin.
Study: NCT00763958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match buprenorphine administered for 3 months
Study: NCT01535820
Drug: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
Study: NCT01535820
Drug: Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
Study: NCT02240433
Drug: LY2157299
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2157299 administered orally
Study: NCT01290406
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00777374
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: epicutanoeus application of a placebo patch
Study: NCT00135005
Drug: AMN107, STI571
Approvals — FDA: no, EMA: no, PMDA: no